{
    "id": 31894,
    "fullName": "CDK5 positive",
    "impact": "unknown",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "CDK5 positive indicates the presence of the CDK5 gene, mRNA, and/or protein.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 1020,
        "geneSymbol": "CDK5",
        "terms": [
            "CDK5",
            "LIS7",
            "PSSALRE"
        ]
    },
    "variant": "positive",
    "createDate": "12/26/2019",
    "updateDate": "12/26/2019",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 19628,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Roscovotine (seliciclib) treatment inhibited growth of CDK2 and CDK5-positive colorectal cancer cell lines in culture (PMID: 29435174).",
            "molecularProfile": {
                "id": 34328,
                "profileName": "CDK2 pos CDK5 pos"
            },
            "therapy": {
                "id": 1129,
                "therapyName": "Seliciclib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 17310,
                    "pubMedId": 29435174,
                    "title": "Characterization of CDK(5) inhibitor, 20-223 (aka CP668863) for colorectal cancer therapy.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29435174"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19626,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, CP668863 treatment inhibited phosphorylation of Fak and Rb1, cell growth, migration, and induced cell cycle arrest in CDK2 and CDK5-positive colorectal cancer cell lines in culture, and inhibited tumor growth and progression in a cell line xenograft model (PMID: 29435174).",
            "molecularProfile": {
                "id": 34328,
                "profileName": "CDK2 pos CDK5 pos"
            },
            "therapy": {
                "id": 9104,
                "therapyName": "CP668863",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 17310,
                    "pubMedId": 29435174,
                    "title": "Characterization of CDK(5) inhibitor, 20-223 (aka CP668863) for colorectal cancer therapy.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29435174"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19627,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AT7519 treatment inhibited growth and induced cell cycle arrest in CDK2 and CDK5-positive colorectal cancer cell lines in culture (PMID: 29435174).",
            "molecularProfile": {
                "id": 34328,
                "profileName": "CDK2 pos CDK5 pos"
            },
            "therapy": {
                "id": 2727,
                "therapyName": "AT7519",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 17310,
                    "pubMedId": 29435174,
                    "title": "Characterization of CDK(5) inhibitor, 20-223 (aka CP668863) for colorectal cancer therapy.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29435174"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 34327,
            "profileName": "CDK5 positive",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 34328,
            "profileName": "CDK2 pos CDK5 pos",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}